Today was the second day of the American Society of Clinical Oncology (ASCO) annual meeting.  Although the day has not been as busy with myeloma-related presentations as tomorrow and Monday will be, there still were some interesting presentations and discussions.

The Beacon published an update earlier today with news from a morning poster session that featured several presentations related to multiple myeloma (see related Beacon news).

This article covers material from an early-afternoon education session that was titled: "Controversies in Myeloma: Induction, Transplant, and Maintenance."

The education session included three talks by …

This year’s American Society of Clinical Oncology (ASCO) annual meeting, which is being held in Chicago, began yesterday and goes through Tuesday.

The first of the myeloma-related sessions at this year's meeting began this morning with a poster session, in which important new research findings were summarized on posters throughout a large conference hall.

MLN9708

This morning’s session included two posters about MLN9708 (ixazomib), an oral drug that works similarly to Velcade (bor­tez­o­mib) and is being in­ves­ti­gated for the treat­ment of multiple myeloma as well as …

During the upcoming annual meeting of the American Society of Clinical Oncology (ASCO), results will be presented from clin­i­cal trials involving poten­tial new drugs under devel­op­ment for the treat­ment of multiple myeloma.

In particular, results for newer, lesser known agents that are in the early stages of clin­i­cal devel­op­ment will take center stage. These agents in­clude obatoclax, siltuximab, daratumumab, and SNS01-T.

According to the recently released ASCO abstracts, the agents showed varying degrees of activity in re­lapsed and refractory myeloma patients. So it will be particularly in­ter­est­ing to …

The 48th annual meeting of the American Society of Clinical Oncology (ASCO) will take place Friday, June 1, through Tuesday, June 5, in Chicago.

More than 25,000 clin­i­cal spe­cialists from all over the world are ex­pec­ted to attend the five-day meeting to discuss the cur­rent re­search in cancer treat­ment and care. The theme for this year’s meeting is “Collaborating to Conquer Cancer.”

The meeting will in­clude many pre­sen­ta­tions and seminars focused spe­cif­i­cally on mul­ti­ple myeloma. The ASCO website cur­rently lists nearly 50 myeloma-based pre­sen­ta­tions (included under “lymphoma and plasma cell disorders”).

The …